Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
http://helmsleytrust.org/program-areas/health-medical-research/
The Leona M. and Harry B. Helmsley Charitable Trust supports a broad spectrum of healthcare and medical research-based programs. The areas supported include Type 1 Diabetes, Digestive Diseases, Rural Healthcare, Cardiology, and a range of other programs and institutions.
Proper citation: Helmsley Charitable Trust (RRID:SCR_005111) Copy
http://www.diabetes.niddk.nih.gov/
Information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established to increase knowledge and understanding about diabetes among patients, health care professionals, and the general public: online, in booklets and fact sheets, by email, and over the phone. To carry out this mission, NDIC works closely with NIDDK''''s Diabetes Research and Training Centers; the National Diabetes Education Program (NDEP); professional, patient, and voluntary associations; Government agencies; and State health departments to identify and respond to informational needs about diabetes and its management. NDIC provides the following informational products and services: * Response to inquiries about diabetes, ranging from information about available patient and professional education materials to statistical data. By phone (8:30 a.m. to 5 p.m. eastern time, M-F), fax, mail, and email. * Publications about diabetes, provided free of copyright, in varying reading levels. Available online or as booklets and brochures. NDIC also sends publications to health fairs and community events. * Referrals to health professionals through the National Library of Medicine''''s MEDLINEplus includes a consumer-friendly listing of organizations that will assist you in your search for physicians and other health professionals. * Exhibits at professional meetings specific to diabetes, as well as cross-cutting professional meetings. NDIC exhibits at 12 professional meetings, each year, including American Diabetes Association Postgraduate Course, American College of Physicians, CDC Diabetes Translation Conference, American Academy of Physician Assistants, American Diabetes Association, American Association of Diabetes Educators, and American Dietetic Association.
Proper citation: National Diabetes Information Clearinghouse (RRID:SCR_006702) Copy
http://www.ohsu.edu/xd/health/services/brain/
A clinical care and research center for neurological conditions such as Alzheimer's, dementia and seizure disorders. It provides a dynamic setting for training healthcare professionals and neuroscience researchers to develop and implement evidence-based treatment.
Proper citation: OHSU Brain Institute (RRID:SCR_008932) Copy
Diabetes research center which provides patient care and performs diabetes research. Its primary aim is to provide a facilitating framework for conducting multi-disciplinary basic and clinical research and to encourage the scientific development of young investigators.
Proper citation: Joslin Diabetes Center (RRID:SCR_009019) Copy
http://purl.bioontology.org/ontology/OGR
Ontology that is used with other ontologies to represent the genetic susceptibility factors of diabetes. This OWL ontology classified the geograhical regions related vocabularies extracted from UMLS.
Proper citation: Ontology of Geographical Region (RRID:SCR_010398) Copy
Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery.Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets.
Proper citation: Structural Genomics Consortium (RRID:SCR_003890) Copy
Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.
Proper citation: reMYND (RRID:SCR_003824) Copy
http://www.blueprint-epigenome.eu/
Consortium to further the understanding of how genes are activated or repressed in both healthy and diseased human cells with a focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukemic counterparts. They will generate at least 100 reference epigenomes and study them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by International Human Epigenome Consortium (IHEC). Access to the data is provided as well as the protocols used to collect the different blood cell types, to perform the different types of epigenomic analyses, etc.). This resource-generating activity will be complemented by hypothesis-driven research into blood-based diseases, including common leukemias and autoimmune disease (Type 1 Diabetes), by discovery and validation of epigenetic markers for diagnostic use and by epigenetic target identification. Since epigenetic changes are reversible, they can be targets for the development of novel and more individualized medical treatments. The involvement of companies will energize epigenomic research in the private sector by the development of smart technologies for better diagnostic tests and by identifying new targets for compounds. Thus the results of the project may lead to targeted diagnostics, new treatments and preventive measures for specific diseases in individual patients, an approach known as "personalized medicine". The Blueprint Data Access Committee will consider applications for access to data sets stored in the European Genome-phenome Archive (EGA) when authorized to do so by the Blueprint consortium and the holders of the original consent documents. Access is conditional upon availability of samples and/or data and signed agreement by the researcher(s) and the responsible employing Institution to abide by policies related to publication, data disposal, ethical approval and confidentiality. At EBI, the ftp site with the data can be found. You can either opt to link to the track hubs yourself or you can add the track hub to a genome browser - UCSC or ENSEMBL. Also Meta Data files and README are available. The data can also be accessed via the BIOMART system.
Proper citation: Blueprint Epigenome (RRID:SCR_003844) Copy
A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden''s largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders.
Proper citation: Diamyd Medical (RRID:SCR_003930) Copy
A drug discovery company focused on small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. They are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilization, structure determination, and fragment-based discovery. Their partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Their objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, ADHD and chronic migraine.
Proper citation: Heptares Therapeutics (RRID:SCR_000499) Copy
https://t1dexchange.org/pages/
Provides access to resources T1D researchers need to conduct clinical studies. Data sets from their clinic registry is openly available, as are new study results. They also offer use of T1D Discovery Tool, which allows users to search different fields from registry data, and T1D Exchange Biobank, which offers specimen types such as serum, plasma, white blood cells, DNA, and RNA.
Proper citation: T1D Exchange (RRID:SCR_014532) Copy
https://diabetescenters.org/centers
Diabetes Research Centers (DRC) is an integrated program of diabetes, endocrinology and metabolism research.
Proper citation: Diabetes Research Centers (RRID:SCR_014535) Copy
https://www.nih.gov/research-training/accelerating-medicines-partnership-amp
Partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical companies and non-profit organizations whose goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. The group explores three major areas of disease: diabetes, Alzheimer's disease, and rheumatoid arthritis and lupus.
Proper citation: Accelerating Medicines Partnership (RRID:SCR_014927) Copy
One of sixteen research centers established by the National Institute of Diabetes and Digestive and Kidney Diseases that fosters research and training in the areas of diabetes and related endocrine and metabolic disorders.
Proper citation: University of California San Francisco Diabetes Research Center (RRID:SCR_015102) Copy
Center which promotes multidisciplinary research in diabetes through raising awareness and interest in fundamental and clinical research, enhancing diabetes research, education and training opportunities, and providing core services that leverage funding and unique expertise.
Proper citation: University of Chicago Diabetes Research and Training Center (RRID:SCR_015114) Copy
Center dedicated to extending prevention and management research of proven efficacy to both clinical and community settings, with the goal of improving the diabetes-related health of Native Americans. The CAIANDTR provides core services and consultation locally, regionally, and nationally in areas relevant to NIDDK's translational research agenda.
Proper citation: Center for American Indian and Alaska Native Diabetes Translational Research (RRID:SCR_015146) Copy
http://www.med.upenn.edu/idom/
Diabetes research center created to address the prevalence of diabetes and obesity. The goal of the center is to support and develop successful approaches to the prevention, treatment, and cure of diabetes mellitus and obesity.
Proper citation: Penn Diabetes Research Center (RRID:SCR_015123) Copy
http://diabetesresearchcenter.dom.wustl.edu
University-affiliated center established to support and enhance research in diabetes and related metabolic diseases. Its long-term goal is the development of new preventive strategies and therapies aimed at improving the lives of Americans with or at risk for diabetes.
Proper citation: Washington University School of Medicine Diabetes Research Center (RRID:SCR_015138) Copy
Portal for providing data and tools to promote understanding and treatment of type 1 diabetes and its complications.Enables browsing, searching, and analysis of human genetic information linked to type 1 diabetes and related traits, while protecting integrity and confidentiality of underlying data.Represents effort to coordinate collection and deposition of genomic and epigenomic data related to type 1 diabetes and its complications.
Proper citation: Type 1 Diabetes Knowledge Portal (RRID:SCR_020936) Copy
https://www.sanger.ac.uk/collaboration/sequencing-idd-regions-nod-mouse-genome/
Genetic variations associated with type 1 diabetes identified by sequencing regions of the non-obese diabetic (NOD) mouse genome and comparing them with the same areas of a diabetes-resistant C57BL/6J reference mouse allowing identification of single nucleotide polymorphisms (SNPs) or other genomic variations putatively associated with diabetes in mice. Finished clones from the targeted insulin-dependent diabetes (Idd) candidate regions are displayed in the NOD clone sequence section of the website, where they can be downloaded either as individual clone sequences or larger contigs that make up the accession golden path (AGP). All sequences are publicly available via the International Nucleotide Sequence Database Collaboration. Two NOD mouse BAC libraries were constructed and the BAC ends sequenced. Clones from the DIL NOD BAC library constructed by RIKEN Genomic Sciences Centre (Japan) in conjunction with the Diabetes and Inflammation Laboratory (DIL) (University of Cambridge) from the NOD/MrkTac mouse strain are designated DIL. Clones from the CHORI-29 NOD BAC library constructed by Pieter de Jong (Children's Hospital, Oakland, California, USA) from the NOD/ShiLtJ mouse strain are designated CHORI-29. All NOD mouse BAC end-sequences have been submitted to the International Nucleotide Sequence Database Consortium (INSDC), deposited in the NCBI trace archive. They have generated a clone map from these two libraries by mapping the BAC end-sequences to the latest assembly of the C57BL/6J mouse reference genome sequence. These BAC end-sequence alignments can then be visualized in the Ensembl mouse genome browser where the alignments of both NOD BAC libraries can be accessed through the Distributed Annotation System (DAS). The Mouse Genomes Project has used the Illumina platform to sequence the entire NOD/ShiLtJ genome and this should help to position unaligned BAC end-sequences to novel non-reference regions of the NOD genome. Further information about the BAC end-sequences, such as their alignment, variation data and Ensembl gene coverage, can be obtained from the NOD mouse ftp site.
Proper citation: Sequencing of Idd regions in the NOD mouse genome (RRID:SCR_001483) Copy
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
You can save any searches you perform for quick access to later from here.
We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the sources that were queried against in your search that you can investigate further.
Here are the categories present within NIF that you can filter your data on
Here are the subcategories present within this category that you can filter your data on
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
